Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To investigate and compare the safety and the pharmacokinetics of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), intranasal DHE spray (Migranal<sup>®</sup>), and intramuscular (IM) DHE injection in healthy subjects. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This was a 2‐part, active‐controlled, 3‐period crossover study over 3 weeks, separated by 1‐week washout periods. In part 1, 3 ascending dosage strengths of STS101 (1.3, 2.6, and 5.2 mg) were administered to 15 healthy subjects with no history of migraine. In part 2, 27 healthy subjects were administered 1 dose each of STS101 5.2 mg, Migranal DHE Mesylate Liquid Nasal Spray 2.0 mg, and IM DHE Mesylate 1.0 mg in a randomized order. Liquid chromatography, tandem mass spectrometry was used to determine plasma levels of DHE and its major metabolite, 8′OH‐DHE. Pharmacokinetic parameters (<i>C</i><sub>max</sub>, <i>T</i><sub>max</sub>, AUC<sub>0‐2 h</sub>, AUC<sub>0‐48 h</sub>, AUC<sub>0‐inf</sub>, and <i>t</i><sub>1/2</sub>) for DHE and metabolite were calculated. Geometric means and 90% confidence intervals of log‐transformed data were calculated and the ratio of means compared. Safety was evaluated by monitoring adverse events, vital signs, electrocardiograms, subjective and objective assessments of nasal signs and symptoms, and changes in laboratory parameters. The study is registered as NCT03874832. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Forty‐three subjects were enrolled and received study medication. Forty completed all study activities, 14 in part 1 and 26 in part 2. In part 1, DHE plasma levels showed a dose‐dependent increase, with STS101 5.2 mg reaching a mean <i>C</i><sub>max</sub> of 1870 pg/mL with a <i>T</i><sub>max</sub> of 23 minutes. In part 2, STS101 5.2 mg showed rapid absorption, achieving mean DHE plasma concentrations of 1230 and 1850 pg/mL at 10 and 15 minutes after administration, respectively. In comparison to Migranal, STS101 5.2 mg showed approximately 2‐fold higher <i>C</i><sub>max</sub> (2175 vs 961 pg/mL), AUC<sub>0‐2 h</sub> (2979 vs 1316 h × pg/mL), and AUC<sub>0‐inf</sub> (12,030 vs 6498 h × pg/mL), respectively. The mean AUC<sub>0‐inf</sub> of STS101 5.2 mg was comparable to IM DHE (12,030 vs 13,650 h × pg/mL). STS101 5.2 mg showed substantially lower variability compared to Migranal for <i>C</i><sub>max</sub> (41% vs 76%), AUC<sub>0‐2 h</sub> (39% vs 75%), and AUC<sub>0‐inf</sub> (39% vs 55%). The incidence of treatment emergent AEs (TEAEs), all mild and transient, reported in parts 1 and 2 combined was 9/15 (60%), 5/15 (33%), and 16/41 (39%) of the subjects after 1.3, 2.6, and 5.2 mg STS101, respectively, and 4/26 (15%) and 5/27 (19%) of the subjects after IM DHE and Migranal, respectively. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>STS101 showed rapid absorption, achieving effective DHE plasma concentrations within 10 minutes. It achieved substantially higher <i>C</i><sub>max</sub>, AUC<sub>0‐2 h</sub> and AUC<sub>0‐inf</sub>, compared to Migranal suggesting potentially better efficacy than Migranal. Its variability was better than Migranal, thus offering improved consistency of response. AUC<sub>0‐inf</sub> was comparable to IM DHE, suggesting prolonged action and low recurrence. Additionally, the <i>C</i><sub>max</sub> was sufficiently low to avoid any significant nausea reported with IV DHE. Thus, STS101 is an easy to administer, non‐injected, acute treatment for migraine, with a favorable tolerability profile and is expected to provide rapid and consistent freedom from pain and associated migraine symptoms without recurrence. </p></section>

Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers

Bioavailability of dexmedetomidine after intranasal administration

Intranasal Versus Intravenous Dexamethasone to Treat Hospitalized COVID-19 Patients: A Randomized Multicenter Clinical Trial

Pharmacokinetic behavior in plasma, cerebrospinal fluid and cerebral cortex after intranasal administration of hydrochloride meptazinol.

Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine

Enhancement of Systemic and CNS Delivery of Meptazinol Hydrochloride by Intranasal Administration to Rats.

A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies

Injectable Dexamethasone Sodium Phosphate Administered Orally? A Pharmacokinetic Analysis of a Common Emergency Department Practice

Safety, Pharmacokinetics/Pharmacodynamics, and Absolute Bioavailability of Dexmedetomidine Hydrochloride Nasal Spray in Healthy Subjects: A Randomized, Parallel, Escalating Dose Study

High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects

Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets

Design and in vitro evaluation of biocompatible dexamethasone-loaded nanoparticle dispersions, obtained from nano-emulsions, for inhalatory therapy

The Pharmacokinetic Profiles of Dexamethasone and Methylprednisolone Concentration in Perilymph and Plasma Following Systemic and Local Administration

The impact of intravenous versus submucosal dexamethasone on short‐term patient response: A randomized controlled trial

Olfaction in chronic rhinosinusitis: comparing two different endonasal steroid application methods

A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone

Microdialysis Pharmacokinetic Study of Scopolamine in Plasma, Olfactory Bulb and Vestibule after Intranasal Administration

Intranasal Dexmedetomidine for the Treatment of Pre-operative Anxiety and Insomnia: A Prospective, Randomized, Controlled, and Clinical Trial

Comparison of Intranasal Steroid Application Using Nasal Saline Irrigation and a Mucosal Atomization Device to Treat Chronic Rhinosinusitis